PURPLE BIOTECH LTD. (PPBT) Form 6-K — Jun 23, 2026
Purple Biotech Ltd. filed a Form 6-K to disseminate its June 2026 corporate presentation, providing an update on its clinical pipeline and financial position. The presentation outlines the development plan for its lead program IM1240, a tri-specific antibody targeting solid tumors, which is expected to submit an IND in 2027. The company reported a cash position of $6.4 million as of March 31, 2026, which it estimates provides a runway into the first half of 2027.
Key figures
- Cash Position
- $6.4 M
- Runway
- H1 2027
- Im1240 ind submission year
- 2027
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.